-
WILLOW BIOSCIENCES REPORTS FOURTH QUARTER AND FISCAL YEAR 2023 FINANCIALS AND OPERATIONS AND FILING OF ITS 2023 AIF
29 Mar 2024 00:47 GMT
… of 2024."
Fourth quarter and recent highlights
Continued … volume anti-infective active pharmaceutical ingredient.
Advanced an … 2024 budget and anticipated expenditures; the achievement of … 47;willow-biosciences-reports-fourth-quarter-and-fiscal-year-2023 …
-
Perimeter Medical Imaging AI Reports Fourth Quarter and Year-End 2023 Financial Results and Provides Corporate Update
29 Mar 2024 00:17 GMT
Conference Call/Webcast Today at 4:30 pm ET
TORONTO and DALLAS, March 28, 2024 /PRNewswire/ - Perimeter Medical Imaging AI, Inc. (TSXV: PINK) (OTC: PYNKF) (FSE: 4PC) ("Perimeter" or the "Company") – a commercial-stage …
-
Burning Rock Reports Fourth Quarter and Full Year 2023 Financial Results
28 Mar 2024 21:16 GMT
… treatment with fulvestrant alone.
Pharma Services
New companion diagnostics … 24% increase from 2022.
Fourth Quarter 2023 Financial Results Revenues … ) a decrease in the expenditure for detection research, and … call to discuss the fourth quarter and full year …
-
Centessa Pharmaceuticals Reports Business Highlights and Financial Results for the Fourth Quarter and Full-Year 2023
28 Mar 2024 20:28 GMT
… CNTA), a clinical-stage pharmaceutical company, today reported recent … financial results for the fourth quarter and full-year … advance toward clinical studies. Fourth Quarter and Full-Year 2023 … conducting clinical trials, future expenditures risks; the risk …
-
NeuroBo Pharmaceuticals Reports Year End 2023 Financial Results and Provides Corporate Update
29 Mar 2024 03:47 GMT
… Company Into the Fourth Quarter of 2024
CAMBRIDGE … assets."
Fourth Quarter 2023 and Subsequent … the fourth quarter of 2024.
About NeuroBo Pharmaceuticals
NeuroBo Pharmaceuticals, … while increasing energy expenditure, thus potentially resulting …
-
Daré Bioscience, Inc. (DARE) Q4 2023 Earnings Call Transcript
29 Mar 2024 02:29 GMT
… , Inc. (NASDAQ:DARE) Q4 2023 Earnings Conference Call March … sales of XACIATO during the fourth quarter. XACIATO became more widely … our R&D expenditure is predicated on ongoing … going through specialty pharmaceutical -- specialty pharmacies, IQVIA isn’t …
-
P3 Health Partners Inc. (PIII) Q4 2023 Earnings Call Transcript
29 Mar 2024 02:28 GMT
… Inc. (NASDAQ:PIII) Q4 2023 Results Conference Call March … P3 also has experience increased fourth quarter costs, but specifically in … network of specialists and pharmaceutical costs that allow us … say, the Part B expenditures have been significantly higher, …
-
Forian Inc. (FORA) Q4 2023 Earnings Call Transcript
29 Mar 2024 02:28 GMT
… Inc. (NASDAQ:FORA) Q4 2023 Earnings Conference Call … . Before going into the fourth quarter in more detail, I first … This could range from pharma service providers developing state-of … being more cautious about capital expenditures and profitability, and, as …
-
atai Life Sciences Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Corporate and Clinical Highlights
28 Mar 2024 11:00 GMT
… disorders, today announced fourth quarter and full year 2023 … safety, tolerability, pharmacokinetics (PK) and pharmacodynamics (PD) of … expected in the fourth quarter of 2024 and … future operations and capital expenditures. Forward-looking statements …
-
Galera Reports Fourth Quarter and Full Year 2023 Financial Results and Recent Corporate Updates
28 Mar 2024 11:00 GMT
MALVERN, Pa., March 28, 2024 (GLOBE NEWSWIRE) -- Galera Therapeutics, Inc. (Nasdaq: GRTX), a biopharmaceutical company focused on developing a pipeline of novel, proprietary therapeutics that have the potential to transform radiotherapy in cancer, today …